Salarius Pharmaceuticals, Inc.

Company Snapshot: Salarius Pharmaceuticals, Inc.

Last Change Volume High Low

Company Overview

Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Client News

  1. Dec 1 2022 Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
  2. Nov 10 2022 Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
  3. Nov 3 2022 Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
  4. Oct 27 2022 Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference